Information Provided By:
Fly News Breaks for May 29, 2015
HRTX
May 29, 2015 | 12:31 EDT
Brean Capital said the fact that Sustol achieved its primary endpoint of superiority over standard of care in a Phase 3 trial should be enough, along with data from its new contract manufacturer, to "easily allow" for an approval in early 1Q16. The firm also thinks Sustol's result can "only logically increase optimism" for the two other drugs being encased within Biochronomer. Brean keeps its Buy rating and $40 price target on Heron Therapeutics.
News For HRTX From the Last 2 Days
There are no results for your query HRTX